Bragar Eagel & Squire, P.C. Is Investigating Enochian, Novartis, Teladoc, and Tupperware and Encourages Investors to Contact the Firm
June 03, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enochian Biosciences, Inc....
Societal CDMO to Report Financial Results for First Quarter 2022 on May 11, 2022
May 04, 2022 16:05 ET
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., May 04, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
January 04, 2022 07:25 ET
|
Arch Biopartners
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial
December 01, 2021 07:35 ET
|
Arch Biopartners
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant...
Axtria Leads Discussion on Pharma’s Advanced Uses of Data Analytics and Artificial Intelligence With 6 Sessions at PMSA 2021 Annual Conference
June 16, 2021 08:00 ET
|
Axtria Inc.
Berkeley Heights, NJ, June 16, 2021 (GLOBE NEWSWIRE) -- With the elevated importance of data analytics and artificial intelligence (AI)-driven intelligence technology systems for a global life...
Rheumatic Fever Treatment Market is estimated with a CAGR of 5.2% during the forecast period - by PMI
June 11, 2021 10:35 ET
|
PMI
Covina, CA, June 11, 2021 (GLOBE NEWSWIRE) -- Rheumatic Fever Treatment Market is estimated with a CAGR of 5.2% during the forecast period. Rheumatic fever is an infectious inflammatory condition...
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
June 10, 2021 07:20 ET
|
Arch Biopartners
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19
May 04, 2021 07:00 ET
|
Arch Biopartners
TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Global Thalassemia Treatment Market is estimated to be US$ 14.7 billion by 2030 with a CAGR of 10.40% during the forecast period - By PMI
April 30, 2021 10:05 ET
|
PMI
Covina, CA, April 30, 2021 (GLOBE NEWSWIRE) -- The Global Thalassemia Treatment Market accounted for US$ 2.3 billion in 2020 and is estimated to be US$ 14.7 billion by 2030 and is anticipated to...
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
April 07, 2021 08:00 ET
|
Immutep Limited
Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...